ClinicalTrials.gg
CompletedNCT04585464Updated Jun 28, 2022

A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults

A Phase 1 interventional study of EDG-5506 and Placebo in Healthy Volunteer and Becker Muscular Dystrophy, sponsored by Edgewise Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-28.

Sponsored by Edgewise Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
23rd of 171
127 · median 25
Started
2020
with 13 others
Phase 1
32 of 232
3 open now
Registered
163rd of 232
by date
Lead sponsor
6 of 232
Edgewise Therapeutics, Inc.

Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 23rd largest by enrollment of the 171 interventional ones that give a count, is one of 14 that started in 2020, is one of 32 in phase 1, and was the 163rd registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

EDG-5506 is an investigational product intended to protect and improve function of dystrophic muscle fibers. This Phase 1 study of EDG-5506 will assess the safety, tolerability, and pharmacokinetics (PK) and of EDG-5506 in adult healthy volunteers and in adults with Becker muscular dystrophy (BMD).

Read the detailed description

Enrolled participants in this study will receive a single oral dose or multiple oral doses of EDG-5506 or a placebo. Blood and urine samples will be collected to measure how EDG-5506 is processed by the body and how the body responds when exposed to EDG-5506. Participants in the single ascending dose part of the study will remain in the clinic for 7 days with a 42-day follow-up period. Participants in the multiple ascending dose part of the study will remain in the clinic for 16 days with a 13-day follow-up period. Safety, tolerability, and pharmacokinetics of EDG-5506 will be assessed in healthy volunteers prior to enrolling participants with Becker muscular dystrophy.

03

Conditions studied

  • Healthy Volunteer
  • Becker Muscular Dystrophy

Keywords

  • Healthy Volunteers
  • Becker Muscular Dystrophy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For all potential participants (Healthy volunteers and BMD): Male or for HV: female. For all: adults aged 18 to 55 years at time of consent.
  • For HVs: Good general health, with no significant medical history, no abnormalities on physical exam
  • For BMD: Diagnosis of BMD based on documentation of mutation(s) in the dystrophin gene and BMD phenotype
  • For BMD: Ability to ambulate
  • For all: Weight greater than or equal to 50 kg and less than 33 kg/m2
  • For HV: Females must be of non-.
  • For all: Males with female partners must use a medically accepted regimen from first dose through 90 days after the last dose
  • For all: Non-smoker and must not have used any tobacco products within 3 months prior to the Screening visit.
  • For all: Able and willing to attend the necessary visits at the study center.

Exclusion criteria

Exclusion Criteria:

  • For all: History of, or physical exam findings indicating endocrine, neurological, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases that, in the opinion of the Investigator, would render the subject being unsuitable for the study.
  • For all: Unable to refrain from strenuous exercise for 3 days prior to check-in and during study.
  • For all: Participation in any other drug study within 30 days or 5 half-lives (whichever is longer) of dosing in the present study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Healthy Volunteer: Single Ascending Dose

    Single oral ascending dose in healthy volunteers Interventions: Drug: EDG-5506 Drug: Placebo

    Drug: EDG-5506 · Drug: Placebo

  • Experimental
    Healthy Volunteer: Multiple Ascending Dose

    Multiple oral ascending doses in healthy volunteers Interventions: Drug: EDG-5506 Drug: Placebo

    Drug: EDG-5506 · Drug: Placebo

  • Experimental
    Becker Muscular Dystrophy: Multiple Ascending Dose

    Multiple oral ascending doses in adults with Becker muscular dystrophy Interventions: Drug: EDG-5506 Drug: Placebo

    Drug: EDG-5506 · Drug: Placebo

Interventions

  • EDG-5506 is administered orally as a single dose or once daily

  • DrugPlacebo

    Placebo is administered orally as a single dose or once daily

06

What researchers measure

Primary outcomes

  1. Incidence, frequency, severity and dose-relationship of adverse events

    Time frame: Up to 42 days of monitoring

  2. Incidence of abnormal laboratory test results (clinical chemistry, hematology, urinalysis, coagulation)

    Time frame: Up to 42 days of monitoring

  3. Incidence of treatment-emergent clinically abnormal electrocardiogram (ECG)

    Time frame: Up to 42 days of monitoring

  4. Incidence of abnormal vital signs

    Time frame: Up to 42 days of monitoring

  5. Incidence of abnormal physical exam findings

    Time frame: Up to 42 days of monitoring

Secondary outcomes

  1. Plasma maximum measured drug concentration (Cmax)

    Time frame: Up to 42 days of testing

  2. Time of maximum concentration (Tmax)

    Time frame: Up to 42 days of testing

  3. Area under the concentration-time curve (AUC)

    Time frame: Up to 42 days of testing

  4. Plasma half-life (T½)

    Time frame: Up to 42 days of testing

  5. Renal clearance (CLR)

    Time frame: Up to 42 days of testing

  6. Drug excreted unchanged in urine (Amt0-24)

    Time frame: Up to 42 days of testing

  7. Fraction excreted in urine (Fe)

    Time frame: Up to 42 days of testing

07

Study locations

1 site
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Nov 2021, 13 months.

Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2020
First posted
Oct 14, 2020
StartActual
Oct 12, 2020
Primary completionActual
Nov 15, 2021
CompletionActual
Dec 27, 2021
Last update
Jun 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04585464
Lead sponsor
Edgewise Therapeutics, Inc.
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Oct 14, 2020
Start date
Oct 12, 2020
Primary completion
Nov 15, 2021
Completion
Dec 27, 2021
Last update
Jun 28, 2022

Study contacts

Medical Director
study director · Edgewise Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevasemten

Start the discussion